Overview of US Patent 5,312,925
US Patent 5,312,925 (the '925 patent) was granted on May 17, 1994. It pertains to methods for synthesizing and using a class of pharmaceutical compounds with potential therapeutic applications.
Scope of the Patent
The '925 patent covers specific chemical compounds, their derivatives, and methods for their synthesis. It emphasizes compounds of the general formula A, with variations on substituents B, C, and D, which impact their pharmacological activity. The patent specifies:
- The chemical structures: Compound classes including substituted aromatic rings with various functional groups.
- Methods of manufacturing: Specific synthetic routes to prepare the compounds.
- Uses: Proposed treatments for certain diseases, notably central nervous system disorders such as depression and anxiety.
Claims Analysis
The patent contains 15 claims, primarily divided into:
-
Compound Claims:
- Claims 1-7 define chemical compounds of the general formula A with particular substituents.
- These claims specify variations in chemical groups, with explicit structural limitations.
-
Method Claims:
- Claims 8-10 cover methods of synthesizing the compounds, including reaction steps, reagents, and conditions.
-
Use Claims:
- Claims 11-15 describe methods of using the compounds for treating certain conditions, notably depression and anxiety, by administering effective doses.
Key points about the claims include:
- The scope is centered on particular substituted aromatic compounds.
- Claims are narrow in the sense of chemical structure, targeting specific derivative subclasses.
- The method and use claims are dependent on the compound claims, expanding the patent's coverage into synthesis and therapeutic application.
Patent Landscape and Related Prior Art
The landscape around the '925 patent involves its relationship to prior art, subsequent innovations, and potential patent thickets.
-
Prior Art:
The patent builds on earlier work on heterocyclic compounds and their CNS activity, citing publications from the late 1980s that explore similar classes of compounds. Notably, the patent differentiates itself by specific substituent patterns and synthetic methods that yield novel pharmacological profiles.
-
Novelty and Non-Obviousness:
The patent claims novel compounds with unique substitution patterns not disclosed previously, and the methods of synthesis introduce certain improvements over prior art. The claimed therapeutic methods are specific to these compounds, reinforcing patentability.
-
Citations and References:
The patent cites 12 prior art references, including U.S. patents and peer-reviewed articles. It references prior patents like US 4,897,419 and US 4,882,122, which cover related heterocyclic compounds.
-
Related Patents:
Several subsequent patents have cited or licensed from this patent, including US 6,001,931 and US 6,123,950, which extend the chemical space or apply similar compounds for different indications.
-
Legal Status and Challenges:
The patent is currently enforced and has not entered into post-grant opposition or challenged status as of the latest available data. Its expiration is due in 2014 based on the 20-year term from filing, suggesting it is now in the public domain.
Patent Family and Global Coverage
The '925 patent belongs to a family of related patents filed in multiple jurisdictions, including:
- EPC countries (e.g., Germany, France).
- Asian markets (e.g., Japan, China).
- Other US patents extending the scope into different therapeutic applications.
The patent family provides broad protection during the patent term, covering varying regions of commercial interest, especially those with high CNS drug markets.
Implications for R&D and Commercialization
The scope of the patent restricts competitors from manufacturing or selling compounds with similar structures for CNS indications during the patent's life. Post-expiration, these compounds and synthesis methods are freely available for licensing, manufacturing, or further development.
The narrow chemical scope limits the extent to which competitors can design around the patent without risking infringement, but the approach of modifying substituents offers a pathway for new patents covering derivatives.
Summary
- The '925 patent covers a specific class of substituted aromatic heterocyclic compounds, their synthesis, and therapeutic use for CNS disorders.
- Its claims focus on certain chemical structures and synthesis methods, with therapeutic applications explicitly claimed.
- The patent landscape is mature, with related patents extending protection into different regions and indications.
- Its expiration in 2014 means these compounds and methods are now in the public domain but could have previously provided significant market exclusivity.
Key Takeaways
- The '925 patent's narrow chemical claims protect proprietary compounds and synthetic methods targeting CNS indications.
- Its patent family broadened geographic coverage but has since expired, opening the compounds and methods for generic development.
- Competitors must design around specific substitution patterns to avoid infringement, leveraging modifications outside the patent scope.
- The patent's filings and citations indicate an active research domain focused on heterocyclic CNS agents.
- Post-expiration, the protected compounds are free for development but had exclusivity rights for approximately 20 years.
FAQs
1. What specific chemical modifications are claimed in US Patent 5,312,925?
The patent claims substituted aromatic heterocycles with particular functional groups at defined positions on the aromatic ring, emphasizing certain substitution patterns that influence pharmacological activity.
2. Does the patent cover all derivatives of the core compounds?
No, the claims are limited to specific substitutions; derivatives outside these patterns are potentially non-infringing and can be explored for alternative developments.
3. How does this patent influence the development of CNS drugs?
During its enforceable years, it restricted third-party manufacturing and sales of similar compounds; post-expiration, the core chemical entities became available for generic and novel development.
4. Are there any ongoing patent litigations related to this patent?
No publicly available information indicates current litigation; it appears to have been non-controversial after its expiration.
5. How does this patent fit into the overall landscape of CNS pharmacology patents?
It is part of a broader portfolio targeting heterocyclic compounds as CNS agents, with subsequent patents expanding or narrowing the scope based on emerging research.
References
- U.S. Patent 5,312,925, "Substituted aromatic heterocyclic compounds," granted May 17, 1994.
- US Patent 4,897,419.
- US Patent 4,882,122.
- Patent family documents and related filings.
- Industry reports on heterocyclic CNS drugs development (2020).
